TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9430375

Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day (group 2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day (group 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simvastatin 160 mg/day (group 1)
Number of subjects: 12
Study: 8214829

Group type: EXPERIMENTAL
Intervention: Brand protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 0
Study: 3307620

Group type: EXPERIMENTAL
Intervention: Zinc acetate lozenges (10 mg), average utilization 5.4 days at an average dose of six lozenges daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Zinc acetate lozenges (10 mg)
Number of subjects: 55
Study: 31914165

Group type: EXPERIMENTAL
Intervention: High-level intervention exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-level intervention exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29422026

Group type: EXPERIMENTAL
Intervention: Letter with motivational content emphasizing financial benefits
Number of subjects: 4767

Group type: EXPERIMENTAL
Intervention: Letter with motivational content emphasizing health benefits
Number of subjects: 4767

Group type: EXPERIMENTAL
Intervention: Letter with motivational content emphasizing values-based benefits
Number of subjects: 4767

Group type: EXPERIMENTAL
Intervention: Referral letter with no motivational content
Number of subjects: 4767

Group type: COMPARATOR
Intervention: No letter (reference group)
Number of subjects: 4767

Group type: EXPERIMENTAL
Intervention: Participants with care and coverage from health plan
Number of subjects: 4767

Group type: EXPERIMENTAL
Intervention: Participants with insurance coverage only
Number of subjects: 4767
Study: 27632874

Group type: EXPERIMENTAL
Intervention: Wobble-board (WB) balance training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resistance tubing (RT)
Number of subjects: 40
Study: 25075991

Group type: EXPERIMENTAL
Intervention: Standard screw insertion technique (ST group)
Number of subjects: 60
Study: 23295793

Group type: EXPERIMENTAL
Intervention: Toremifene citrate 20 mg
Number of subjects: 1590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1590
Study: 21426748

Group type: COMPARATOR
Intervention: PCI group (50 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative therapy group (50 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative therapy group (50 patients) with MLA < 4.0 mm(2)
Number of subjects: 100
Study: 17962712

Group type: EXPERIMENTAL
Intervention: Echinacea (ECH) 8000 mg/d (5 x 400 mg x 4 times/d for 28 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Echinacea (ECH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study: 14724051

Group type: EXPERIMENTAL
Intervention: 5-Hydroxy-L-tryptophan (5-HTP) 3-200 mg/kg ip
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-Hydroxy-L-tryptophan (5-HTP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral 5-Hydroxy-L-tryptophan (5-HTP) 1.2-2.0 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-Hydroxy-L-tryptophan (5-HTP) with L-valine
Number of subjects: 0
Study: 11420028

Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate (FP) 400 micrograms/day administered into each nostril twice a day for 45 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cetirizine 10 mg daily as a single dose for 45 days
Number of subjects: 43
Study: 9445199

Group type: EXPERIMENTAL
Intervention: Oral antibiotic prophylaxis consisting of novobiocin and rifampin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Observation alone (Control)
Number of subjects: 26
Study: 8037567

Group type: EXPERIMENTAL
Intervention: Pulsatile flow during CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonpulsatile flow during CPB
Number of subjects: 30
Study: 2524362

Group type: EXPERIMENTAL
Intervention: Dihydroxyprogesterone acetophenide 150 mg and estradiol enanthate 10 mg (DHPA/E2-EN)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 25 mg and estradiol cypionate 5 mg (MPA/E2-C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate 50 mg and estradiol valerate 5 mg (NET-EN/E2-V)
Number of subjects: 50

Group type: COMPARATOR
Intervention: IUD (control group)
Number of subjects: 50
Study: 30093143

Group type: EXPERIMENTAL
Intervention: External pancreatic stents
Number of subjects: 185

Group type: COMPARATOR
Intervention: Internal pancreatic stents
Number of subjects: 185
Study: 28263039

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29566322

Group type: EXPERIMENTAL
Intervention: Visual Inspection of the Cervix with Acetic acid (VIA)
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Visual Inspection of the Cervix with Lugol's Iodine (VILI)
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Visual Inspection of the Cervix with Acetic acid (VIA) among severely immuno-compromised HIV positive participants
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Visual Inspection of the Cervix with Lugol's Iodine (VILI) among severely immuno-compromised HIV positive participants
Number of subjects: 1160
Study: 24708857

Group type: EXPERIMENTAL
Intervention: SCAP method (dose reduction of antipsychotics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal regimen (control group)
Number of subjects: 0
Study: 21983797

Group type: EXPERIMENTAL
Intervention: Heavy resistance exercise (70-80% of 1RM)
Number of subjects: 34
Study: 21097440

Group type: EXPERIMENTAL
Intervention: Plasmaslyte A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ringer lactate solution
Number of subjects: 60
Study: 17667483

Group type: EXPERIMENTAL
Intervention: Individual trauma-focused cognitive-behavioral therapy (CBT) for 10 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waitlist (WL) for 10 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Individual trauma-focused cognitive-behavioral therapy (CBT)
Number of subjects: 24
Study: 16123753

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 782
Study: 12548586

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged treatment with bisphosphonates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers of bone turnover
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates as adjuvant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates for preventing bone loss
Number of subjects: 0
Study: 10368446

Group type: EXPERIMENTAL
Intervention: Tilt testing in children with neurocardiac syncope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noninvasive autonomic function tests (Valsalva, handgrip, deep breathing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) measures
Number of subjects: 0
Study: 8673558

Group type: EXPERIMENTAL
Intervention: Plaque area measurements in carotid arteries, n = 19
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plaque area measurements in common carotid artery, n = 20
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intima-media thickness measurements in carotid bulb
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intima-media thickness measurements in common femoral artery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quantitative measurements of plaques in femoral arteries
Number of subjects: 50
Study: 1906120

Group type: EXPERIMENTAL
Intervention: Nadolol, 40-160 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anaprilin, 80-240 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control placebo
Number of subjects: 40
Study: 6869418

Group type: EXPERIMENTAL
Intervention: Cooperative learning procedures
Number of subjects: 48

Group type: COMPARATOR
Intervention: Individualistic learning procedures
Number of subjects: 48
Study: 30951837

Group type: EXPERIMENTAL
Intervention: Peer coach-led pain self-management intervention (6 months, patient-peer coach pairs talk twice per month)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control group receiving a class on pain and pain self-management
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Peer coach-led pain self-management intervention
Number of subjects: 215
Study: 27838341

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behaviour therapy (CBT) for 9 weeks
Number of subjects: 13
Study: 26672920

Group type: EXPERIMENTAL
Intervention: Cycling Aerobic Interval Training (AIT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 45
Study: 25322754

Group type: EXPERIMENTAL
Intervention: NV1FGF (2.5 ml at 0.2 mg/ml or 0.4 mg/dl)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: NV1FGF (up to 32 mg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 22588946

Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Procaine hydrochloride 5 mg/kg
Number of subjects: 110
Study: 19247636

Group type: EXPERIMENTAL
Intervention: Alcohol 0.4 g/kg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g/kg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol (both doses)
Number of subjects: 48
Study: 16675148

Group type: EXPERIMENTAL
Intervention: Anti-tobacco PSAs
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Anti-marijuana PSAs
Number of subjects: 229
Study: 15691618

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 57
Study: 12095569

Group type: EXPERIMENTAL
Intervention: Prophylactic C1 whole brain external beam irradiation, 18 Gy in 2 Gy/fraction for 9 fractions
Number of subjects: 353

Group type: COMPARATOR
Intervention: Institutions placing 1-4 patients on study
Number of subjects: 353

Group type: COMPARATOR
Intervention: Institutions placing > or =5 patients on study
Number of subjects: 353

Group type: COMPARATOR
Intervention: 1996-1997
Number of subjects: 353

Group type: COMPARATOR
Intervention: 1998-2001
Number of subjects: 353
Study: 10440439

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 7538959

Group type: EXPERIMENTAL
Intervention: HES (Hydroxy‐Ethyl‐Starch) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Outpatients group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inpatients group
Number of subjects: 20
Study: 2166934

Group type: EXPERIMENTAL
Intervention: Azithromycin (5-day therapy)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Josamycin (10-day therapy)
Number of subjects: 89
Study: 7016627

Group type: EXPERIMENTAL
Intervention: Pyritinol 200 mg three times a day for a period of 6 weeks
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 270
Study: 30376651

Group type: EXPERIMENTAL
Intervention: Self-compassion prompt
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 167
Study: 27932570

Group type: EXPERIMENTAL
Intervention: losartan/amlodipine (100/5 mg) once a day for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: losartan hydrochlorothiazide (100/12.5 mg) once a day for 3 months
Number of subjects: 60
Study: 27427867

Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice pack applied six times on the perineum for 20 minutes, reducing temperature between 10 and 15 °C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-cryotherapy (water bag unable to reduce temperature significantly)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-cryotherapy
Number of subjects: 80
Study: 24204594

Group type: EXPERIMENTAL
Intervention: Specialist-taught PE program (intervention group)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Control group (generalist classroom teachers)
Number of subjects: 708
Study: 21421767

Group type: EXPERIMENTAL
Intervention: Glucose beverage consumption to bolster self-regulatory resources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angry rumination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: State rumination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced self-control capacity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (unpleasant task)
Number of subjects: 0
Study: 18389188

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/day plus CPA/EE (2 mg CPA/35 microg EE)
Number of subjects: 29
Study: 16856548

Group type: EXPERIMENTAL
Intervention: 0.6 mg x kg(‐1) of rocuronium with sevoflurane
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.6 mg x kg(‐1) of rocuronium with propofol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.9 mg x kg(‐1) of rocuronium with sevoflurane
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.9 mg x kg(‐1) of rocuronium with propofol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 39

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 39
Study: 14552083

Group type: EXPERIMENTAL
Intervention: QB-based Kt/V estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QB prescribed according to patient's body weight
Number of subjects: 0
Study: 10902748

Group type: EXPERIMENTAL
Intervention: CRP <6 mg/liter
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: CRP >=25 mg/liter
Number of subjects: 359
Study: 8883124

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with conjugated equine estrogen, 0.3‐0.625 mg/day for 12 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Parathyroidectomy followed by calcitriol therapy (0.25 micrograms b.i.d. for 12 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Parathyroidectomy followed by calcium replacement (1 g/day for 12 months)
Number of subjects: 15
Study: 1423336

Group type: EXPERIMENTAL
Intervention: i.v. levodopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenylalanine (LNAA)
Number of subjects: 0
Study: 3159318

Group type: EXPERIMENTAL
Intervention: Intradermal skin testing with tubocurarine and atracurium (diluted 1 in 1,000)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Anaesthesia using atracurium or tubocurarine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intradermal skin testing
Number of subjects: 22
Study: 30661698

Group type: EXPERIMENTAL
Intervention: 60,000 IU vitamin D3 orally/month for 6 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: AED without vitamin D3
Number of subjects: 83
Study: 29642282

Group type: EXPERIMENTAL
Intervention: N6022 (5 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 26983754

Group type: EXPERIMENTAL
Intervention: Xuebijing injection (XBJ)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 24614628

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 40
Study: 22190621

Group type: EXPERIMENTAL
Intervention: Observing a clockwise force field (CWFF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observing a counter-clockwise force field (CCWFF)
Number of subjects: 0
Study: 19240085

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ, 10-20 mg/day)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Quetiapine (QUE, 300-700 mg/day)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Quetiapine (QUE)
Number of subjects: 346
Study: 18619511

Group type: EXPERIMENTAL
Intervention: Electrically heated cigarette smoking system (EHCSS, Series K)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional cigarette (CC)
Number of subjects: 90
Study: 17561988

Group type: EXPERIMENTAL
Intervention: Tilarginine (a non‐specific inhibitor of nitric oxide synthase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15486802

Group type: EXPERIMENTAL
Intervention: Propofol (group P, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Midazolam (group M, n = 50)
Number of subjects: 100
Study: 11244226

Group type: EXPERIMENTAL
Intervention: Metronidazole 1% gel
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10756746

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (group B), given in one dose
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 182
Study: 8304056

Group type: EXPERIMENTAL
Intervention: Indomethacin bolus injection followed by continuous infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Periods of hypoxia (17% oxygen) and hypercapnia (2‐4% CO2)
Number of subjects: 0
Study: 3731679

Group type: EXPERIMENTAL
Intervention: amiflamine, 5 mg bid (n = 8)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo, 1 capsule twice a day (n = 4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: oral tyramine (400 mg)
Number of subjects: 12
Study: 30791040

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (≥60 s)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Immediate cord clamping (<10 s)
Number of subjects: 265
Study: 29778773

Group type: EXPERIMENTAL
Intervention: 100PG liquid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PG-based liquids (2PG:98VG, 20PG:80VG, 55PG:45VG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 30
Study: 27338467

Group type: EXPERIMENTAL
Intervention: Dietary counselling to increase fruit intake (+1 serving/day; 150 g/day)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Dietary counselling to increase dairy intake (+1 serving/day; 200-250 g/day)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Dietary counselling to increase vegetable intake (+2 servings/day; 150 g/day)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Intervention group (dietary counselling)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 109
Study: 25006720

Group type: EXPERIMENTAL
Intervention: Hypothermia (rectal temperature of 33 to 34°C for 72 hours within 6 hours after birth)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control (standard care alone)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control
Number of subjects: 325
Study: 21543653

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Baseline NGAL
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Baseline cystatin C
Number of subjects: 88
Study: 19339053

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 16807260

Group type: EXPERIMENTAL
Intervention: Filter-only (A2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SP-only (A3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Filter and SP (A4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No filter, no SP (A1)
Number of subjects: 40
Study: 15301918

Group type: EXPERIMENTAL
Intervention: Butorphanol (0, 0.5, 1, and 2 mg/70 kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cold-water stimulus (2 degrees C) during butorphanol administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study: 12174334

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg daily for 21 days)
Number of subjects: 16
Study: 10503166

Group type: EXPERIMENTAL
Intervention: Lentinan 2 mg i.v. once a week for eight weeks
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Lentinan 5 mg i.v. once a week for eight weeks
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Lentinan 10 mg i.v. once a week for eight weeks
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Lentinan 1 mg i.v. twice a week for 12 weeks
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Lentinan 5 mg i.v. twice a week for 12 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (vehicle containing mannitol plus dextran 40) i.v. twice a week for 12 weeks
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Lentinan in combination with didanosine (ddI)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Didanosine (ddI) alone
Number of subjects: 98
Study: 7521940

Group type: EXPERIMENTAL
Intervention: Nimodipine (1 mg-2 mg intravenously)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Dextran 40,000 (standard therapy)
Number of subjects: 88
Study: 2519936

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (1.5 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 21
Study: 31014423

Group type: EXPERIMENTAL
Intervention: calsurf treatment + conventional treatment
Number of subjects: 208

Group type: COMPARATOR
Intervention: conventional treatment
Number of subjects: 208
Study: 28244416

Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m2) plus gemcitabine (50‐125 mg/m2) (C/G)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study: 25542343

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy adapted for health anxiety (delivered by nurses)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Standard care (delivered by naive therapists)
Number of subjects: 444
Study: 23984312

Group type: EXPERIMENTAL
Intervention: Bromocriptine (BEC) 2.5 mg, initially 1 tablet with subsequent increase to three times a day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PBO), initially 1 tablet with subsequent increase to three times a day
Number of subjects: 28